Literature DB >> 8223927

Delayed regional metabolic actions of phencyclidine.

X M Gao1, O Shirakawa, F Du, C A Tamminga.   

Abstract

Phencyclidine (PCP), a psychotomimetic drug of abuse, produces mental changes and manifestations in humans which are reminiscent of schizophrenia, though the mechanism of these actions remains unknown. We report here a biphasic time course of PCP action on regional cerebral glucose metabolism extending over 48 h. A single dose of PCP (8.6 mg/kg) produces an initial increase in glucose metabolism (at 3 h) and a later decrease in glucose metabolism (at 24 h) without a return to baseline until 48 h. A single lower dose of PCP (0.86 mg/kg), a dose which is considered selective for action at the NMDA-PCP receptor, produces no early metabolic change (at 3 h), but replicates the regional hypometabolism albeit less intense at 24 h. The delayed cerebral hypometabolism does not appear to be related to PCP-induced intracellular vacuolization, seen in the retrosplenial cortex. These metabolic changes may be associated with the psychotomimetic effects of PCP and thus may be relevant to psychosis in humans.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8223927     DOI: 10.1016/0014-2999(93)90926-9

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  13 in total

1.  Spatial memory deficits in a virtual reality eight-arm radial maze in schizophrenia.

Authors:  Elena A Spieker; Robert S Astur; Jeffrey T West; Jacqueline A Griego; Laura M Rowland
Journal:  Schizophr Res       Date:  2011-12-09       Impact factor: 4.939

2.  MK801 induces late regional increases in NMDA and kainate receptor binding in rat brain.

Authors:  X M Gao; C A Tamminga
Journal:  J Neural Transm Gen Sect       Date:  1995

3.  Persisting changes in brain glucose uptake following neurotoxic doses of phencyclidine which mirror the acute effects of the drug.

Authors:  G D Ellison; A S Keys
Journal:  Psychopharmacology (Berl)       Date:  1996-08       Impact factor: 4.530

4.  Delayed changes in neural visinin-like calcium-binding protein gene expression caused by acute phencyclidine administration.

Authors:  Y Kajimoto; O Shirakawa; T Kuno; N Nishino; H Nakai
Journal:  J Neural Transm Gen Sect       Date:  1995

Review 5.  The subchronic phencyclidine rat model: relevance for the assessment of novel therapeutics for cognitive impairment associated with schizophrenia.

Authors:  Sanna K Janhunen; Heta Svärd; John Talpos; Gaurav Kumar; Thomas Steckler; Niels Plath; Linda Lerdrup; Trine Ruby; Marie Haman; Roger Wyler; Theresa M Ballard
Journal:  Psychopharmacology (Berl)       Date:  2015-06-14       Impact factor: 4.530

6.  Subchronic and chronic PCP treatment produces temporally distinct deficits in attentional set shifting and prepulse inhibition in rats.

Authors:  Alice Egerton; Lee Reid; Sandie McGregor; Susan M Cochran; Brian J Morris; Judith A Pratt
Journal:  Psychopharmacology (Berl)       Date:  2008-04-23       Impact factor: 4.530

7.  Social memory in mice: disruption with an NMDA antagonist and attenuation with antipsychotic drugs.

Authors:  Xue-Min Gao; Gregory I Elmer; Beverley Adams-Huet; Carol A Tamminga
Journal:  Pharmacol Biochem Behav       Date:  2008-12-10       Impact factor: 3.533

8.  The interactive effects of ketamine and nicotine on human cerebral blood flow.

Authors:  Laura M Rowland; Lori Beason-Held; Carol A Tamminga; Henry H Holcomb
Journal:  Psychopharmacology (Berl)       Date:  2010-03       Impact factor: 4.530

Review 9.  Modelling prefrontal cortex deficits in schizophrenia: implications for treatment.

Authors:  J A Pratt; C Winchester; A Egerton; S M Cochran; B J Morris
Journal:  Br J Pharmacol       Date:  2008-03       Impact factor: 8.739

10.  Neurochemical changes in the rat prefrontal cortex following acute phencyclidine treatment: an in vivo localized (1)H MRS study.

Authors:  Isabelle Iltis; Dee M Koski; Lynn E Eberly; Christopher D Nelson; Dinesh K Deelchand; Julien Valette; Kamil Ugurbil; Kelvin O Lim; Pierre-Gilles Henry
Journal:  NMR Biomed       Date:  2009-08       Impact factor: 4.044

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.